
Supplementary Table 1. Number of APOBEC3 specific hypermutations relative to the 2018_NIGERIA_MT903340 mpox reference sequence. Analysis performed with the Hypermut program through the Los Alamos National Laboratory website

Isolate (GISAID Accession ID)	G->A	C->T	Total
2022_ROMANIA_EPI_ISL_17018429	31	19	50
2022_ROMANIA_EPI_ISL_17018430	32	19	51
2022_ROMANIA_EPI_ISL_17018431	32	20	52
2022_ROMANIA_EPI_ISL_17018432	58	55	113
2022_ROMANIA_EPI_ISL_17018433	32	21	53
2022_ROMANIA_EPI_ISL_17018434	31	19	50
2022_ROMANIA_EPI_ISL_17018435	92	93	185
2022_ROMANIA_EPI_ISL_17018436	31	19	50
2022_ROMANIA_EPI_ISL_17018437	37	36	73
2022_ROMANIA_EPI_ISL_17018438	31	19	50
2022_ROMANIA_EPI_ISL_17018439	32	20	52
2022_ROMANIA_EPI_ISL_17821080	31	19	50
2022_ROMANIA_EPI_ISL_17821081	31	20	51
2022_ROMANIA_EPI_ISL_17821082	33	23	56
2023_ROMANIA_EPI_ISL_17821083	31	26	57
2023_ROMANIA_EPI_ISL_17821084	31	24	55
2023_ROMANIA_EPI_ISL_17821085	32	25	57
2023_ROMANIA_EPI_ISL_17821086	31	25	56
2023_ROMANIA_EPI_ISL_17821087	31	26	57
2023_ROMANIA_EPI_ISL_17821088	32	27	59
Average	**36**	**28**	**64**

Supplementary Figure 1.

A)




A) Timeline of medical interventions and sample collections for the ART-naive patient who presented with multiple infections. For the MTB treatment, he was given isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). The antiretroviral therapy consisted of FTC/TAF and DTG according to the current guidelines, which also recommended delaying the start of ART for 1 month after the start of MTB treatment. After the PCR diagnosis of mpox infection, the patient also started treatment with tecovirimat for 1 month.

B)

L1 (06 Jan) EPI_ISL_17821083	L2 (26 Jan) EPI_ISL_17821084	L3 (15 Feb) EPI_ISL_17821085	R1 (06 Jan) EPI_ISL_17821086	R2 (26 Jan) EPI_ISL_17821087	R3 (15 Feb) EPI_ISL_17821088
	B10.5R T34del		*B10.5R* T34del		
	B10.5R D35del		*B10.5R* D35del		
		A23R R123Q			
A23R P145S				*A23R* P145S	*A23R* P145S
E11L V619I	*E11L* V619I	*E11L* V619I	*E11L* V619I	*E11L* V619I	*E11L* V619I
			F1L E339K	*F1L* E339K	*F1L* E339K
F4L E253K	*F4L* E253K	*F4L* E253K	*F4L* E253K	*F4L* E253K	*F4L* E253K
G8L D212N	*G8L* D212N	*G8L* D212N	*G8L* D212N	*G8L* D212N	*G8L* D212N
G10R R194H	*G10R* R194H	*G10R* R194H	*G10R* R194H	*G10R* R194H	*G10R* R194H
Q1L M107I	*Q1L* M107I	*Q1L* M107I	*Q1L* M107I	*Q1L* M107I	*Q1L* M107I

B) Overview of mutations according to the GISAID database (gene and effect on translation) for the 6 sequences obtained from our extensively monitored ART-naive HIV-infected patient. The two reservoirs are labelled as L (skin lesion) and R (rectal swab).

C)



C) Summary of the evolution of both the HIV and mpox infections (relative viral load normalized to the maximum measured levels) and the immunological reconstitution of the patient (in terms of rising CD4+ and CD8+ T cell counts) following the start of ART at the end of 2022